Global Statistics on Skin Cancer

Key Takeaways

• Skin cancer is the most commonly diagnosed cancer in many high-income countries, with incidence rates continuing to rise globally.
• Australia and New Zealand report the highest skin cancer rates per capita, while rates are increasing rapidly in Europe and North America.
• Basal cell carcinoma (BCC) is the most prevalent type worldwide, followed by squamous cell carcinoma (SCC) and melanoma.
• Melanoma, though less common, accounts for the vast majority of skin cancer deaths due to its aggressive metastatic potential.
• Early detection and sun protection interventions remain the most effective tools for reducing both incidence and mortality.

Global Statistics on Skin Cancer: Incidence and Diagnosis Worldwide

Global statistics on skin cancer reveal a disease of striking prevalence and accelerating incidence. According to the World Health Organization (WHO), between 2 and 3 million non-melanoma skin cancers and approximately 132,000 melanoma cases are diagnosed globally each year. When non-melanoma cases are included in national cancer registries—which is inconsistent across countries—the actual burden is estimated to be far higher, making skin cancer one of the most underreported major cancers in the world.

The Global Cancer Observatory (GLOBOCAN), maintained by the International Agency for Research on Cancer (IARC), estimates that melanoma alone accounted for over 324,000 new cases in 2020. Projections suggest this figure will continue to climb due to aging populations, lifestyle changes, and cumulative ultraviolet (UV) radiation exposure across generations. These trends highlight the urgent need for standardized international data collection and cross-border public health collaboration.

Incidence rates vary considerably based on skin phototype, geographic latitude, occupational UV exposure, and access to preventive care. Fair-skinned populations in sun-intensive regions face disproportionately higher risk, while darker skin tones are associated with lower incidence but often later-stage diagnosis, leading to worse outcomes. This diagnostic disparity underscores the importance of equitable screening practices across all populations.

Skin Cancer Prevalence by Country and Region

Skin cancer prevalence by country reflects a complex interplay of environmental, genetic, and behavioral factors. Australia consistently ranks among the countries with the highest skin cancer burden globally, with approximately two in three Australians diagnosed with skin cancer before the age of 70, according to the Australian Institute of Health and Welfare (AIHW). New Zealand reports similarly elevated rates, largely attributable to high UV index levels, outdoor cultural norms, and historically fair-skinned populations.

In the United States, the Centers for Disease Control and Prevention (CDC) estimates that more than 5 million cases of non-melanoma skin cancer are treated annually, making it the nation’s most diagnosed cancer. European countries, particularly those in northern latitudes such as Norway, Sweden, and Denmark, have seen sharp increases in melanoma incidence over recent decades, correlating with trends in recreational sun exposure and the use of tanning beds.

Regions closer to the equator, including parts of Sub-Saharan Africa, South Asia, and Latin America, report lower overall incidence of UV-related skin cancers in lighter-skinned groups. However, specific subtypes such as mucosal melanoma and acral lentiginous melanoma—which are not primarily UV-driven—are proportionally more common in populations with darker skin tones. These regional variations complicate global comparisons and emphasize the need for region-specific data collection strategies.

Region / Country	Estimated Annual Melanoma Incidence (per 100,000)	Notable Risk Factor
Australia & New Zealand	33–40	High UV index, fair-skinned population
United States	~22	Sun exposure, tanning bed use
Northern Europe (Norway, Sweden)	~20–25	Recreational sun exposure, low melanin
Sub-Saharan Africa	<5	Higher melanin; late-stage diagnosis common
East Asia	~1–3	Lower UV sensitivity; acral subtypes more common

Most Common Types of Skin Cancer and Their Global Distribution

Understanding the most common types of skin cancer globally is essential for interpreting incidence data accurately. Skin cancers are broadly categorized into non-melanoma skin cancers (NMSCs) and melanoma, with NMSCs constituting the overwhelming majority of diagnoses worldwide.

Basal cell carcinoma (BCC) is the most frequently diagnosed skin cancer globally, originating in the basal cells of the epidermis. BCC grows slowly, rarely metastasizes, and carries a favorable prognosis when treated early. Squamous cell carcinoma (SCC) is the second most common type, arising from the squamous cells that form the outer layers of the skin. SCC carries a greater risk of spreading to regional lymph nodes compared to BCC, particularly in immunocompromised patients. Together, BCC and SCC account for the vast majority of skin cancer diagnoses, though many countries still exclude them from official cancer registry totals.

Melanoma, while representing a smaller percentage of total diagnoses, is responsible for the majority of skin cancer deaths due to its high metastatic potential. It originates in melanocytes—the pigment-producing cells—and can spread rapidly to distant organs if not detected early. Less common subtypes include Merkel cell carcinoma, dermatofibrosarcoma protuberans, and cutaneous lymphomas, each with distinct epidemiological profiles and geographic distributions.

The global distribution of these types is shaped by UV radiation patterns, genetic susceptibility, and population demographics. BCC and SCC predominate in UV-intense regions among fair-skinned populations. In contrast, acral lentiginous melanoma—a subtype that develops on the palms, soles, or under the nails—accounts for a larger share of melanoma diagnoses in Asian, African, and Hispanic populations, highlighting that skin cancer risk is not exclusively tied to sun exposure.

Skin Cancer Mortality Rates and Emerging International Trends

Skin cancer mortality rates worldwide present a nuanced picture: while survival rates for most NMSCs are very high, melanoma continues to drive the bulk of skin cancer-related deaths. According to GLOBOCAN 2020 data, melanoma was responsible for approximately 57,000 deaths globally in that year. Mortality rates are highest in Australia, New Zealand, and parts of northern Europe, largely mirroring incidence patterns, though improved early-detection programs have begun to stabilize death rates in some high-income countries.

Emerging international skin cancer data and trends suggest that while mortality from melanoma has declined in countries with robust screening infrastructure and access to targeted immunotherapies, low- and middle-income countries continue to face rising death tolls. This disparity is driven by limited access to dermatological care, late-stage presentation, and a lack of national skin cancer screening programs. The WHO has recognized this growing inequity as a public health priority in its skin health global report.

Among the most significant emerging trends is the documented increase in skin cancer diagnoses among younger age groups. Historically associated with older adults, melanoma is now appearing more frequently in individuals under 40, attributed partly to recreational tanning behavior and increased outdoor activity without adequate sun protection. This shift has prompted public health campaigns in multiple countries targeting adolescents and young adults specifically.

Advances in treatment—particularly checkpoint inhibitor immunotherapy and targeted BRAF/MEK inhibitor therapies—have substantially improved survival outcomes for advanced melanoma, previously one of the most lethal cancers. However, these therapies remain inaccessible in many parts of the world due to cost and healthcare system limitations. Expanding access to both preventive care and life-extending treatments represents one of the most pressing challenges in global oncology today.

Frequently Asked Questions

How many people are diagnosed with skin cancer globally each year?

Millions of skin cancer cases are diagnosed worldwide annually. GLOBOCAN data from 2020 estimates over 324,000 new melanoma cases globally, while non-melanoma skin cancers—primarily basal cell and squamous cell carcinomas—add several million more diagnoses each year. Because many countries do not include non-melanoma cases in official cancer registries, the true global figure is likely significantly higher than published statistics suggest.

Which countries have the highest skin cancer rates?

Australia and New Zealand consistently report the highest skin cancer rates globally, with melanoma incidence reaching 33 to 40 cases per 100,000 people annually. The United States and several northern European countries, including Norway and Sweden, also report elevated rates. These patterns are strongly associated with fair-skinned populations, high UV index environments, and cultural behaviors such as outdoor recreation and historical use of tanning beds.

What factors are driving the global increase in skin cancer cases?

Several factors contribute to rising skin cancer incidence worldwide, including increased recreational UV exposure, aging global populations, depletion of the ozone layer in certain regions, and historically low rates of sun-protective behavior. Growing awareness and improved diagnostic capabilities have also led to more cases being identified and reported. Additionally, the popularity of tanning beds has contributed to earlier-onset melanoma diagnoses, particularly among younger adults and women.